Frozen shoulder is a common fibroproliferative disease characterized by the insidious onset of pain and restricted range of shoulder movement with a significant socioeconomic impact. The pathophysiological mechanisms responsible for chronic inflammation and matrix remodeling in this prevalent fibrotic disorder remain unclear; however, increasing evidence implicates dysregulated immunobiology. IL-17A is a key cytokine associated with inflammation and tissue remodeling in numerous musculoskeletal diseases, and thus, we sought to determine the role of IL-17A in the immunopathogenesis of frozen shoulder. We demonstrate an immune cell landscape that switches from a predominantly macrophage population in nondiseased tissue to a T cell–rich environment in disease. Furthermore, we observed a subpopulation of IL-17A–producing T cells capable of inducing profibrotic and inflammatory responses in diseased fibroblasts through enhanced expression of the signaling receptor IL-17RA, rendering diseased cells more sensitive to IL-17A. We further established that the effects of IL-17A on diseased fibroblasts was TRAF-6/NF-κB dependent and could be inhibited by treatment with an IKKβ inhibitor or anti–IL-17A antibody. Accordingly, targeting of the IL-17A pathway may provide future therapeutic approaches to the management of this common, debilitating disease.Frozen shoulder, also known as adhesive capsulitis, is a very common painful condition of the shoulder that can affect up 10% of people of working age (
1). Clinically, it manifests as progressively limited joint movement in all directions associated with pain and loss of function (
2). Frozen shoulder is more prevalent in women, mainly affecting those in the fifth and sixth decades of life, and is the third most common cause of musculoskeletal disability in the United States and European Union (
3). While often thought of as a self-limiting disease, the majority of patients suffer permanent disability at long-term follow up, with some patients reporting painful symptoms at 6-y postdisease onset (
4), costing the US healthcare system in excess of $85 million per annum (
5). Numerous rehabilitative, medical, and surgical therapies are available (
2); however, current research does not support a clear treatment strategy, and none are derived from an understanding of the molecular mechanisms underpinning disease pathology.The principal structure affected in this disease is the shoulder capsule, with pathological changes culminating in tissue fibrosis. Inflammation is known to play a crucial role in tissue fibrosis, and various proinflammatory cytokines have been implicated in driving the progression of many fibrotic diseases (
6–
8). Frozen shoulder capsular tissue has demonstrated inflammatory cell influx (
9), dysregulated expression of alarmins (HMGB-1, Tenascin C, IL-33, S100A8, S100A9) (
10,
11), inflammatory proteins (IL-1α, IL-1β, IL-6, TGF-β, COX-1, COX-2, TNF-α) (
12,
13), matrix regulating (matrix metalloproteinases [MMPs] and tissue inhibitors of metalloproteinases [TIMPs]) (
12,
14), and markers of stromal fibroblast activation (PDPN, VCAM, MCAM) (
15,
16). Thus, the presence of immune cells, dysregulated inflammatory/matrix interactions, and activated fibroblasts allude to a significant and targetable immune component in the pathogenesis of frozen shoulder.IL-17A is a cytokine known to mediate inflammation (
17), fibrosis (
18), and pain signaling (
19). It is the founding member of the IL-17 cytokine family and the signature cytokine of the Th17 T-helper cell population, although it is also expressed by γδ T cells, innate lymphoid, and natural killer cells (
20,
21) The IL-17 receptor family contains five members (A through E), and IL-17A binds and exerts its downstream effects through an IL-17RA/RC complex (
21). Fibroblasts are among the most responsive cells to IL-17A and, following IL-17RA/RC binding, induce mitogen-activated protein kinases, nuclear factor kappa-b (NF-κB), phosphoinositide 3 kinase (PI3K), and C/EBP signaling pathways. The resultant IL-17 “signature” includes, but is not limited to, the promotion of proinflammatory cytokine, chemokine, and matrix metalloproteinase expression from multiple target cells, including stromal fibroblasts (
17,
18,
22–
26). IL-17A signaling has been identified and successfully targeted as a clinical therapy in a host of chronic inflammatory conditions including ankylosing spondylitis and psoriatic arthritis (
27–
29). Furthermore, we have recently shown the translational potential of IL-17A in the soft tissue musculoskeletal condition, tendinopathy (
26,
30).Frozen shoulder has a cellular and molecular profile that is intriguingly similar to the manifestation of IL-17A signaling. Based on these observations, we hypothesized that IL-17A signaling may be involved in mediating the inflammatory and tissue remodeling changes present in frozen shoulder in a similar manner to that which is involved in tendinopathy (
26). The purpose of this study was, firstly, to characterize the immune cell and expression of IL-17A in human frozen shoulder capsule tissue compared to healthy control capsule and, secondly, to interrogate IL-17A signaling in frozen shoulder fibroblasts in vitro to ultimately determine if any pathogenic effects could be impeded. Herein, we report T cell–driven IL-17A production and signaling, which induces the fibrotic features of frozen shoulder. Importantly, we demonstrate that manipulation of cytokine (IL-17A) signaling and response pathways can be a therapeutic opportunity for this debilitating disease.
相似文献